




PHARMACEUTICAL 2018

Sio Gene Therapies Inc.
Rank 229 of 342





PHARMACEUTICAL 2018

Sio Gene Therapies Inc.
Rank 229 of 342



The relative strengths and weaknesses of Sio Gene Therapies Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Sio Gene Therapies Inc. compared to the market average is the variable Assets, Current, increasing the Economic Capital Ratio by 79% points. The greatest weakness of Sio Gene Therapies Inc. is the variable Liabilities, Non-Current, reducing the Economic Capital Ratio by 48% points.

The company's Economic Capital Ratio, given in the ranking table, is 21%, being 24% points below the market average of 46%.

Input Variable	Value in 1000 USD
Assets, Current	219,688
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	46,266
Liabilities, Non-Current	51,436
Other Assets	2,709
Other Compr. Net Income	378
Other Expenses	430
Other Liabilities	0
Other Net Income	0
Other Revenues	0
Property and Equipment	142
Research and Development	134,800
Selling, General and Administrative Expense	45,721

Output Variable	Value in 1000 USD
Assets	222,539
Liabilities	97,702
Expenses	180,951
Revenues	0
Stockholders Equity	124,837
Net Income	-180,951
Comprehensive Net Income	-180,762
Economic Capital Ratio	21%